ArticleClinical parkinsonism & related disorders2026
Multitype hand writing as a digital marker for Parkinson's disease.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Handwriting impairment is a distinctive symptom of movement disorders (MDs), such as Parkinson's disease (PD) and Parkinsonian syndrome (PDS). Objectives: Custom-designed digital handwriting (DHW) tools were developed to strengthen the diagnosis of MDs. Methods: Participants with MDs from the Neurology and PET departments at the First Affiliated Hospital of Guangzhou Medical University were recruited to perform digital handwriting (DHW) tasks, which included drawing a line and a cube, and writing a sentence in Chinese (Ch), English (E), and Korean (K). AV133 PET-CT/MRI was used to detect the expression of vesicular monoamine transporter 2 (VMAT2) in the brain. An attention-based one-dimensional convolutional neural network (1D-CNN) model was developed to evaluate DHW indicators for PD diagnosis. Results: A total of 197 participants with MDs and 160 matched controls were included, among whom 55 MD patients underwent AV133 PET-CT/MR for VMAT2 quantification. The machine learning model demonstrated that the DHW scores showed excellent discrimination between MDs and controls, with an area under the receiver operating characteristic curve (AUC) of 0.982. In subgroup analyses, the L + E + K and L + E + K + Cu task combinations effectively distinguished PD from PDS, with AUC values of 0.727 and 0.717, respectively. The diagnostic agreement between the DHW and PET-VMAT2 results reached 85.45%. PET-AV133 imaging revealed a significant 33.7% downregulation of VMAT2 expression throughout the putamen in PD patients compared with PDS patients, with dramatic reductions in the posterior putamen. DHW scores from the L + E + K + Cu task combination were significantly correlated with VMAT2 expression in the caudate nucleus (q = 0.0005), specifically within the bilateral caudate heads and bodies. Conclusions: Custom-designed DHW tasks can serve as effective digital markers for PD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.